原发性肝癌患者血清miR-15b-5p、miR-145与TACE治疗预后不良的关系

摘要/Abstract

摘要： 目的探讨原发性肝癌患者血清微小RNA(miR)-145、miR-15b-5p与经肝动脉化疗栓塞术(TACE)预后的相关性。方法选取启东市人民医院于2020年3月至2022年4月收诊的129例原发性肝癌患者,根据患者术后3个月预后分成预后良好组与预后不良组。分析原发性肝癌患者预后不良的影响因素。分析miR-145、miR-15b-5p及二者联合对原发性肝癌预后不良的预测价值。随访2年,记录患者生存情况。结果预后不良组门静脉癌栓、包膜不完整、肿瘤边缘为连续性结节比例高于预后良好组(P<0.05),预后不良组的miR-15b-5p、中性粒细胞与淋巴细胞比值(NLR)比预后良好组高,预后不良组比预后良好组低(P<0.05)。包膜完整性、血清miR-145、肿瘤边缘、血清miR-15b-5p为原发性肝癌患者预后不良的影响因素(P<0.05)。血清miR-145、血清miR-15b-5p与血清miR-145联合血清miR-15b-5p预测原发性肝癌患者预后不良的曲线下面积(AUC)分别为0.815、0.805、0.902(P<0.05)。血清miR-15b-5p低水平患者的生存率比高水平患者低(P<0.05),血清miR-145高水平患者的生存率比低水平患者高(P<0.05);miR-145与miR-15b-5p呈负相关(P<0.05)。结论血清miR-15b-5p联合miR-145水平在预测肝癌TACE术后预后中具有更高价值。

关键词: 原发性肝癌, 微小RNA-15b-5p, 微小RNA-145, 经肝动脉化疗栓塞术, 预后

Abstract: Objective To investigate the correlation between serum microRNA (miR) -145 and miR-15b-5p and the prognosis of patients with primary liver cancer after transcatheter arterial chemoembolization (TACE).Methods A total of 129 patients with primary liver cancer admitted to Qidong People's Hospital from March 2020 to April 2022 were selected. According to their 3-month postoperative prognosis, the patients were divided into good prognosis group and bad prognosis group. The study aimed to analyze the influencing factors of poor prognosis in patients with primary liver cancer and the predictive value of miR-145, miR-15b-5p and their combination in predicting the poor prognosis of primary liver cancer.The patients were followed up for 2 years and their survival was recorded.Results The proportion of portal vein cancer thrombus, incomplete capsule and continuous tumor margin in poor prognosis group was higher than good prognosis group (P<0.05). The miR-15b-5p and neutrophil to lymphocyte ratio (NLR) in the poor prognosis group were higher than good prognosis group, but lower in the poor prognosis group (P<0.05). Envelope integrity, serum miR-145, tumor margin, and serum miR-15b-5p were the influencing factors for poor prognosis of patients with primary liver cancer (P<0.05).The area under the curve (AUC) of serum miR-145, serum miR-15b-5p, and a combination of serum miR-145 and serum miR-15b-5p in predicting poor prognosis of patients with primary liver cancer were 0.815, 0.805 and 0.902, respectively (P<0.05). The survival rate of patients with low serum miR-15b-5p level was lower than patients with high serum miR-15b-5p level (P<0.05), and the survival rate of patients with high serum miR-145 level was higher than patients with low serum miR-145 level (37.21%) (P<0.05). Serum miR-145 was negatively correlated with miR-15b-5p (P<0.05).Conclusion The combination of serum miR-15b-5p and miR-145 levels has a higher value in predicting the prognosis of liver cancer after TACE.

Key words: Primary liver cancer, Microrna-15b-5p, Microrna-145, Transcatheter hepatic arterial chemoembolization, Poor prognosis, Predictive value

张自强, 陈凯荣, 吴俊, 刘金龙, 马峰. 原发性肝癌患者血清miR-15b-5p、miR-145与TACE治疗预后不良的关系[J]. 肝脏, 2024, 29(12): 1503-1507.

ZHANG Zi-qiang, CHEN Kai-rong, WU Jun, LIU Jin-long, MA Feng. Relationship between serum miR-15b-5p and miR-145 and poor prognosis after TACE treatment in patients with primary liver cancer[J]. Chinese Hepatolgy, 2024, 29(12): 1503-1507.

/ 推荐

参考文献

[1] Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022,77(6):1598-1606.
[2] Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma[J]. Biosci Trends, 2021,15(3):155-160.
[3] Li Q J, He M K, Chen H W, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial[J]. J Clin Oncol, 2022,40(2):150-160.
[4] Li S, Wei X, He J, et al. The comprehensive landscape of miR-34a in cancer research[J]. Cancer Metastasis Rev, 2021,40(3):925-948.
[5] Fu B, Liu W, Zhu C, et al. Circular RNA circBCBM1 promotes breast cancer brain metastasis by modulating miR-125a/BRD4 axis[J]. Int J Biol Sci, 2021,17(12):3104-3117.
[6] Dobre M, Poenaru R C, Niculae A M, et al. Increased levels of miR-15b-5p and miR-20b-5p in pancreatic ductal adenocarcinoma with hepatic metastases[J]. Genes (Basel), 2023,14(8):1577.
[7] Li H, Zhao S, Chen X, et al. MiR-145 modulates the radiosensitivity of non-small cell lung cancer cells by suppression of TMOD3[J]. Carcinogenesis, 2022,43(3):288-296.
[8] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中国实用外科杂志,2022,42(3):241-273.
[9] Llovet J M, Lencioni R. mRECIST for HCC: Performance and novel refinements[J]. J Hepatol, 2020,72(2):288-306.
[10] Pan L N, Ma Y F, Hu J A, et al. Hsa_circ_0003288 facilitates tumor progression by targeting miR-145 in non-small cell lung cancer cells[J]. Cancer Biomark, 2022,35(4):349-357.
[11] Wei C, Jiang P, Li G, et al. 5,7,2,5-tetrahydroxy-8,6-dimethoxyflavone up-regulates miR-145 expression and inhibits proliferation of gastric cancer cells[J]. Arch Med Sci, 2022,18(3):753-760.
[12] Tulinsky L, Dzian A, Matakova T, et al. Overexpression of the miR-143/145 and reduced expression of the let-7 and miR-126 for early lung cancer diagnosis[J]. J Appl Biomed, 2022,20(1):1-6.
[13] Asai S, Goto Y, Tanigawa K, et al. MiR-15b-5p inhibits castration-resistant growth of prostate cancer cells by targeting the muscarinic cholinergic receptor CHRM3[J]. FEBS Lett, 2023,597(8):1164-1175.
[14] 王朝英,徐军,罗靖茹,等. 原发性老年肝癌患者TACE前后miR-145、CD44变化及近期疗效[J]. 中国老年学杂志,2022,42(14):3419-3423.
[15] 陈钰,陈斌斌,赵静,等. MRI联合血清AFP-L3和VEGF水平预测TACE术治疗的原发性肝癌患者预后的价值[J]. 实用肝脏病杂志,2023,26(4):556-559.
[16] 庄琰,杜森,张进,等. 基于MRI影像学指标分析影响原发性肝癌患者预后的危险因素及验证模型构建[J]. 中国CT和MRI杂志,2023,21(7):100-102.
[17] Lin Z, Liu J. lncRNA DQ786243 promotes hepatocellular carcinoma cell invasion and proliferation by regulating the miR?15b?5p/Wnt3A axis[J]. Mol Med Rep, 2021,23(5):318.
[18] 叶小荣,潘德标,王理富. miR-145-3p在肝癌中的表达及其对肝癌细胞生长的调控作用[J]. 世界华人消化杂志,2020,28(17):827-833.
[19] 秦丽丽,张东成,仲思. miR-15b-5p调控PI3K/AKT/mTOR信号通路对肾癌细胞凋亡及氧化应激反应的影响[J]. 中国中西医结合肾病杂志,2022,23(2):149-153.
[20] Lin Z, Liu J. lncRNA DQ786243 promotes hepatocellular carcinoma cell invasion and proliferation by regulating the miR?15b?5p/Wnt3A axis[J]. Mol Med Rep, 2021,23(5):25.
[21] 陈义,黄平,陈进,等. 循环miR-338-5p、miR-15b-5p和miR-21-5p作为肝细胞癌的潜在肿瘤标记物[J]. 第三军医大学学报,2015,37(17):1720-1726.